Introduction
============

Colorectal cancer is the third most common cancer and the fourth leading cause of cancer-related death in Korea \[[@b1-crt-2016-069]\]. As the development of chemotherapeutic agents improved treatment outcomes, the median overall survival (OS) of metastatic colorectal cancer (mCRC) patients treated with chemotherapy higher to over 20 months. The efficacy of anti--epidermal growth factor receptor (EGFR) monoclonal antibodies (mAbs) is one important development. Cetuximab--- a chimeric monoclonal antibody that targets EGFR---demonstrated improved efficacy outcomes in mCRC patients harboring wild-type *KRAS* exon 2 through all treatment continuums, from the first-line to salvage-line treatments \[[@b2-crt-2016-069],[@b3-crt-2016-069]\].

*RAS* genes are common oncogenes in human cancer and present in 30%-40% of colorectal cancers \[[@b4-crt-2016-069]\]. Of the three major isoforms of *RAS*---including *KRAS*, *NRAS*, and *HRAS*---mutant *KRAS* exon 2 is the most prevalent *RAS* mutation in colorectal cancer. Additional *RAS* mutations beyond the *KRAS* exon 2 can be found in 15%-27% of tumors harboring wild-type *KRAS* exon 2, and they reduce the efficacy of anti-EGFR mAbs--based treatment \[[@b5-crt-2016-069]-[@b8-crt-2016-069]\]. In the FIRE-3 trial (folinic acid, 5-fluorouracil and irinotecan \[FOLFIRI\] plus cetuximab vs. FOLFIRI plus bevacizumab as first-line treatment for patients with mCRC), OS in *RAS* wild-type subgroup after extended *RAS* testing was higher compared with patients with mCRC with the wild-type *KRAS* exon 2 \[[@b5-crt-2016-069]\]. The PRIME (The Panitumumab Randomized Trial in Combination with Chemotherapy for Metastatic Colorectal Cancer to Determine Efficacy) and PEAK (panitumumab plus 5-fluorouracil, folinic acid and oxaliplatin \[FOLFOX\] or bevacizumab plus FOLFOX in patients with mCRC) trials added weight to this argument \[[@b6-crt-2016-069],[@b7-crt-2016-069]\]. Extended *RAS* testing beyond *KRAS* exon 2 is accepted and recommended in various countries, including the United Kingdom, France, Japan, and United States, before treatment with anti-EGFR mAbs. The current recommendations are derived from retrospective subgroup analyses of first-line trials \[[@b6-crt-2016-069],[@b9-crt-2016-069],[@b10-crt-2016-069]\]; however, there are few trials that report the impact of extended *RAS* testing under salvage-line settings in Asian patients.

There are several methods for *RAS* testing, and their sensitivities vary. Sanger sequencing and real-time polymerase chain reaction (PCR) are approved for analyzing *KRAS* exon 2 mutations in Korea. Sanger sequencing for *RAS* mutations beyond *KRAS* exon 2 was also recently approved but was not used before 2015. Although Sanger sequencing is widely used in clinical practice, this test has a low sensitivity with about 20% of detection limit \[[@b11-crt-2016-069]\]. In addition, the test is laborious and time-consuming. Real-time PCR is more sensitive than Sanger sequencing; however, it is not approved for testing extended *RAS* beyond *KRAS* exon 2 in Korea. OncoMap is a technology that can detect mutations in cancer-related genes with speed, accuracy, and a sensitivity with about 5% of detection limit using the mass spectrometer \[[@b12-crt-2016-069]\]. OncoMap can detect specific mutations with the following process. First, the target DNA is amplified. Second, single base extension is performed. After the single base extension reaction, small DNA products that have unique mass value according to mutation are generated. These differences are measured by mass spectrometer.

The first aim of our study was to evaluate if the high-throughput genotyping platform---OncoMap---can detect *RAS* mutations accurately in *KRAS* exon 2 wild-type patients determined by Sanger sequencing. The second aim was to evaluate the impact of extended *RAS* in chemotherapyrefractory mCRC patients treated with cetuximab.

Materials and Methods
=====================

1. Study population
-------------------

To evaluate the impact of extended *RAS* testing, we identified wild-type *KRAS* exon 2 patients who were diagnosed with histologically confirmed mCRC. Three hundred and sixteen consecutive patients were treated at our hospital between December 2003 and June 2013 with cetuximab as third-line or later treatments after oxaliplatin, irinotecan, and fluoropyrimidines failed. Patients were excluded if they had tumor tissue inappropriate for further genetic analyses (n=89). Two hundred and twenty-seven patients were finally included in our study population. An objective response analysis was available for 202 patients with measurable disease. The Institutional Review Board of Asan Medical Center approved this study.

2. Tumor tissue sampling and mutational analysis
------------------------------------------------

Formalin-fixed paraffin embedded (FFPE) tissues of primary or metastatic lesions were used for the genetic analyses. The FFPE tissue blocks were retrieved from archives, reviewed by a pathologist, and the tumor portion was marked and cut for genetic analyses. Genomic DNA was extracted from FFPE tissue using the QIAamp DNA Tissue kit (Qiagen, Hilden, Germany) according to the manufacturer's instructions. The extracted genomic DNA was then analyzed using the currently available OncoMap ver. 4.0 \[[@b13-crt-2016-069]\]; 471 mutations in 41 cancer-related oncogenes can be detected using the OM_V4_Core format. For this study, the OncoMap-Colon Panel included 11 hot spots: codons 12 and 13 (exon 2), codon 61 (exon 3), and codons 117 and 146 (exon 4), both in the *KRAS* and *NRAS* oncogenes, and exon 15 in the *BRAF* oncogenes.

3. Statistical analysis
-----------------------

The primary study objective was to determine the frequency of additional *RAS* mutations that were detected by the high-throughput genotyping platform (OncoMap) in mCRC patients with wild-type *KRAS* exon 2 documented by Sanger sequencing. The secondary objective was to evaluate whether more sensitive *RAS* testing would predict the efficacy of cetuximab treatment. Objective response rate (ORR) was determined using Response Evaluation Criteria in Solid Tumors ver. 1.1. Progression-free survival (PFS) was defined as the time from the administration of cetuximab to disease progression or death-related to disease, and OS as the time to death from any cause.

All statistical analyses were explorative. Fisher exact test was used to compare the ORR between the *RAS* groups (wild-type vs. mutant). In addition the odds-ratio and 95% confidence intervals were calculated for ORR by *RAS* status. The Kaplan-Meier method was used to estimate PFS and OS, and log-rank test was applied to compare both endpoints by *RAS* status. The hazard ratio (HR) and corresponding 95% confidences intervals for PFS and OS were calculated using univariate Cox proportional hazards methods. Two-tailed null hypotheses of no difference were rejected if p-values were less than 0.05, or, equivalently, if the 95% confidence intervals (CIs) of risk point estimates excluded 1. No alpha adjustment was applied for multiple significance testing. All data were analyzed using the SPSS ver. 21.0 (IBM Corp., Armonk, NY).

Results
=======

1. Baseline characteristics of the study subjects
-------------------------------------------------

The clinical characteristics of the 227 study patients are presented in [Table 1](#t1-crt-2016-069){ref-type="table"}. The median age was 56 years, and 152 patients (67%) were male. Of these 227 patients, 165 patients (72.7%) had metastatic disease at diagnosis, whereas 62 patients (27.3%) had recurrent disease. The most common site of metastasis was the liver (64.8%). All patients had been treated with fluorouracil and irinotecan. There were no significant differences in any baseline characteristics by *RAS* mutation status. The prior treatment period from the date of first-line chemotherapy to the date of cetuximab administration, was 17.8 months in the wild-type *RAS* group and 17.4 months in the mutant *RAS* group. The median duration of cetuximab treatment was 13 weeks (interquartile range, 6 to 24.9 weeks).

2. Additional *RAS* mutations
-----------------------------

All 227 study patients were documented with tumors harboring wild-type *KRAS* exon 2 by Sanger sequencing. After reanalysis with OncoMap, 25.1% of these patients (57 of 227) were identified as harboring additional *RAS* mutations (i.e., any mutant *RAS* group) ([Table 2](#t2-crt-2016-069){ref-type="table"}). Of note, 11% of the patients (25 of 227) had a mutated *KRAS* exon 2, which was not detected by Sanger sequencing. Beyond *KRAS* exon 2, 14.1% of patients (32 of 227) had mutations in *KRAS* exons 3 or 4, or *NRAS* exons 2, 3, or 4 ([Table 2](#t2-crt-2016-069){ref-type="table"}). Of the 202 patients with confirmed wild-type *KRAS* exon 2, 15.8% (32 of 202) had *RAS* mutations beyond *KRAS* exon 2. The detailed frequencies of the *RAS* mutations are listed in [Table 2](#t2-crt-2016-069){ref-type="table"}.

3. Clinical outcomes according to *RAS* mutations
-------------------------------------------------

The treatment outcomes are presented in [Table 3](#t3-crt-2016-069){ref-type="table"}. Among the 227 patients known to harbor wild-type *KRAS* exon 2, as determined by Sanger sequencing, the PFS was 3.7 months(95% CI, 2.9 to 4.6) and the median OS was 11.4 months (95% CI, 9.9 to 12.9). Objective responses were observed in 64 of the 202 patients evaluated for a response (31.7%). The odds ratio was 16.53 (95% CI, 3.87 to 70.55; p \< 0.001). Separation of the Kaplan-Meier curve was observed between groups ([Fig. 1](#f1-crt-2016-069){ref-type="fig"}) by the new *RAS* Mutational status. The median OS was 11.9 months (95% CI, 10.1 to 13.7) in the wild-type *RAS* group according to the OncoMap and 8.4 months (95% CI, 6.5 to 10.3) in the mutant *RAS* group (p=0.006). The PFS differed significantly between groups (4.8 months \[95% CI, 4.2 to 5.5\] vs. 1.8 months \[95% CI, 1.7 to 2.0\]; p \< 0.001). Of the 57 patients with *RAS* mutations detected by OncoMap, 55 patients' disease progressed following cetuximab therapy.

4. *BRAF* mutation
------------------

The *BRAF* V600E mutation was detected in 6.2% of the study patients (14 of 227). *BRAF* mutations were found only in individuals harboring wild-type RAS tumors. Among the 170 patients with wild-type RAS tumors according to the OncoMap, the OS was 12.8 months (95% CI, 11.4 to 14.2) in the wild-type *BRAF* group and 2.3 months (95% CI, 0 to 4.9) in the mutant *BRAF* group. The PFS in the non-mutated *BRAF* patients was significantly longer than in the mutant *BRAF* patients (5.0 months \[95% CI, 4.3 to 5.6\] vs. 1.1 months \[95% CI, 0.4 to 1.7\]; HR, 0.10; 95% CI, 0.05 to 0.18). None of the 12 evaluable patients in the mutant *BRAF* group showed a response to cetuximab.

5. Survival in patients with wild-type *RAS* and wild-type *BRAF* mCRC
----------------------------------------------------------------------

In patients with *RAS* WT and *BRAF* wild-type mCRC (all wild-type group, n=156), PFS was 5.0 months (95% CI, 4.3 to 5.6) compared with 1.6 months (95% CI, 1.3 to 2.0) in mutant RAS or mutant *BRAF* patients (any mutant group, n=71). OS was 12.8 months (95% CI, 11.4 to 14.2) and 7.6 months (95% CI, 5.2 to 10.0) in the all wild-type group and any mutant group, respectively.

Discussion
==========

We found that 14.1% of additional *RAS* mutations in Korean mCRC populations exist beyond *KRAS* exon 2. To the best of our knowledge, this is the first study to report a need for extended *RAS* testing in Asian mCRC patients treated with cetuximab. This is consistent with reports in Western populations in a variety of settings, from first-line to salvage therapies \[[@b5-crt-2016-069],[@b6-crt-2016-069],[@b8-crt-2016-069],[@b9-crt-2016-069],[@b14-crt-2016-069]\]. We earlier found frequency of *KRAS* exon 2 mutations in a Korean case series to be similar to the Western studies \[[@b15-crt-2016-069]\]. The frequency of extended *RAS* mutations in our current case series likewise does not differ from Western populations.

Another interesting finding of our current study was that we detected additional *KRAS* exon 2 mutations (11% of the total) that could not be found using Sanger sequencing, a technique that is widely used in general clinical practice. Furthermore, the patients with mutated *RAS* according to OncoMap showed significantly worse outcome compared to wild-type *RAS* patients under cetuximab treatment. Atreya et al. \[[@b14-crt-2016-069]\] suggest that additional *KRAS* mutations could be detected in 20%-30% of wild-type *KRAS* patients using routine testing if the tumors with rare mutant *KRAS* clones are examined using a higher sensitivity assay. Trials such as the PRIME, FIRE-3, and the CRYSTAL trial did not report the additional detection of the *KRAS* exon 2 mutations because they used a sensitive method for detecting *KRAS* exon 2 mutations (real-time PCR and pyrosequencing).

Among the patients in the FIRE-3 trial treated with first-line cetuximab-FOLFIRI chemotherapy, re-analysis of survival after extended *RAS* testing showed that median OS in wild-type *RAS* patients is longer than wild-type *KRAS* patients (33.1 months vs. 28.7 months, respectively) \[[@b5-crt-2016-069]\]. Among the patients who received first-line panitumumab-FOLFOX in the PRIME trial, PFS (9.6 to 10.1 months) and OS (23.9 to 26 months) improved according to the results of extended *RAS* testing \[[@b6-crt-2016-069]\]. However, there have been few studies that investigated the role of extend *RAS* testing under salvage settings in mCRC patients. Our present data suggest that the benefit of extended *RAS* testing could be applied to chemotherapy-refractory mCRC patients treated with cetuximab.

OncoMap may be able to overcome the weaknesses of Sanger sequencing. First, OncoMap is a more sensitive method. Furthermore, there are many advantages of OncoMap, such lower tissue requirement, shorter turnaround time, and automated methodology. In addition, it can test other mutations of interest at the same time. There is always debate however, as to whether more accurate tests are always better. The different analytical techniques used to evaluate *RAS* Mutational status have not influenced the predictive value of *RAS* mutations \[[@b16-crt-2016-069]\]. Moreover, some researchers report that patients with tumors containing rare mutant *RAS* cells might clinically benefit from anti-EGFR mAbs \[[@b9-crt-2016-069],[@b14-crt-2016-069]\]. Further research is needed to define the cutoff values for the detection limit of *RAS* mutations.

In our study, two patients responded to treatment despite having mutant *KRAS* tumors, detected by OncoMap. They had *KRAS* mutations (Q61H in exon 3 and G12D in exon 2) and were treated with cetuximab in combination with irinotecan. They lived for 6.9 months and 11.1 months with out cancer progression. In the case with G12D in exon 2, the tumor with small *RAS* clones might be responding to cetuximab/irinotecan chemotherapy, because OncoMap is more sensitive than Sanger sequencing.

The clinical usefulness of identifying the *BRAF* mutation for anti-EGFR mAbs therapy is unclear. In the pooled analysis of CRYSTAL (FOLFIRI plus cetuximab in mCRC) and OPUS (cetuximab plus FOLFOX as first-line treatment for mCRC), the *BRAF* mutation was a poor prognostic marker in patients with wild-type *KRAS* mCRC who were treated with cetuximab in combination with chemotherapy as the first-line treatment \[[@b17-crt-2016-069]\]. In the retrospective analysis of the earlier PRIME trial, the survival outcomes in mutant *BRAF* patients (n=24) without *RAS* mutations were inferior to those of wild-type *BRAF* patients (PFS, 6.1 months \[95% CI, 3.7 to 10.7\] vs. 10.8 months \[95% CI, 9.4 to 12.4\]; OS, 10.5 months \[95% CI, 6.4 to 18.9\] vs. 28.3 months \[95% CI, 23.7 to not evaluated\]) \[[@b6-crt-2016-069]\]. In chemotherapy refractory settings, the role of the *BRAF* mutation in anti-EGFR mAbs therapy is not wellestablished due to the small number of mutant *BRAF* patients \[[@b18-crt-2016-069],[@b19-crt-2016-069]\]. According to our current data, although our sample size was small, the OS and PFS in mutant *BRAF* patients (n=14) were significantly less than the wild-type *BRAF* patients.

This study had some notable limitations. First, this was a retrospective analysis from a single center. Second, there was no control group. However, this represents the first study to investigate the frequency and impact of *RAS* mutations beyond *KRAS* exon 2 in an Asian population. Our data suggest that false-negative results could occur in routine clinical practice using Sanger sequencing, which has been an approved methodology that is required for extended *RAS* testing.

Conclusion
==========

In conclusion, Sanger sequencing is not sufficient for selecting candidates for cetuximab treatment. High throughput extended *RAS* genotyping is feasible and identifies patients who might benefit from cetuximab treatment.
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![(A) Overall survival by *RAS* mutation status. (B) Progression-free survival by *RAS* mutation status. *RAS* WT, wildtype according to OncoMap; *RAS* MT, mutant according to OncoMap; all patients, WT *KRAS* exon 2 according to Sanger sequencing; +, censored time.](crt-2016-069f1){#f1-crt-2016-069}

###### 

Study patient characteristics

  Characteristic                No. (%)
  ----------------------------- ------------
  **Age, median (IQR, yr)**     56 (49-63)
  **Sex**                       
   Female                       75 (33.0)
   Male                         152 (67.0)
  **Primary site**              
   Colon                        112 (49.3)
   Rectum                       115 (50.7)
  **Histology**                 
   Well differentiated          13 (5.7)
   Moderately differentiated    185 (81.5)
   Poorly differentiated        14 (6.2)
   Signet ring cell             3 (1.3)
   Undetermined                 12 (5.3)
  **No. of metastatic sites**   
   1                            113 (49.8)
   ≥ 2                          114 (50.2)
  **Metastatic sites**          
   Liver with other sites       85 (37.4)
   Liver only                   62 (27.3)
   Other sites                  80 (35.2)
  **Setting**                   
   Metastatic disease           165 (72.7)
   Recurrent disease            62 (27.3)
  **Treatment lines**           
   3                            162 (71.4)
   4                            52 (22.9)
   5                            9 (4)
   6                            4 (1.8)
  **Prior fluoropyrimidine**    227 (100)
  **Prior oxaliplatin**         221 (97.4)
  **Prior irinotecan**          227 (100)
  **Prior bevacizumab**         46 (20.3)
  **Combination drugs**         
   Irinotecan                   145 (63.9)
   Cetuximab monotherapy        82 (36.1)

###### 

Additional *RAS* mutations according to OncoMap

  Mutation                          No.
  ------------------------- ------- -----
  ***KRAS* (n=46)**                 
   Exon 2 (25/227, 11.0%)   G12C    2
                            G12D    10
                            G12R    1
                            G12S    2
                            G12V    4
                            G13D    5
                            G13S    1
   Exon 3 (9/227, 4.0%)     Q61H    7
                            Q61L    1
                            Q61R    1
   Exon 4 (12/227, 5.3%)    A146T   7
                            A146V   2
                            K117N   3
  ***NRAS* (n=11)**                 
   Exon 2 (6/227, 2.6%)     G12A    1
                            G12D    3
                            G12V    1
                            G13V    1
   Exon 3 (5/227, 2.2%)     Q61H    1
                            Q61K    2
                            Q61R    2

###### 

Clinical outcomes by *RAS* mutations

                             Sanger sequencing   OncoMap              p-value          
  -------------------------- ------------------- -------------------- ---------------- --
  **ORR, n (%)**             64/202 (32.2)       62/152 (40.8)        2/50 (4)         
   OR (95% CI)                                   16.53 (3.87-70.55)   \< 0.001         
  **PFS, median (95% CI)**   3.7 (2.9-4.6)       4.8 (4.2-5.5)        1.8 (1.7-2.0)    
   HR (95% CI)                                   0.44 (0.32-0.61)     \< 0.001         
  **OS, median (95% CI)**    11.4 (9.9-12.9)     11.9 (10.1-13.7)     8.4 (6.5-10.3)   
   HR (95% CI)                                   0.65 (0.47-0.88)     0.006            

WT, wild-type; ORR, objective response rate (202 patients with measurable disease were analyzed as part of the response evaluation); OR, odds ratio; CI, confidence interval; PFS, progression-free survival; HR, hazard ratio; OS, overall survival.
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